Current Trends to Decrease Myopia Progression Survey: An IPOSC Global Study
Eedy Mezer, MD; Ofira Zloto, MD; Sonal K. Farzavandi, MD; Rosario M. Gomez-de-Liano, MD, PhD; Derek T. Sprunger, MD; Tamara Wygnanski-Jaffe, MD
Rambam Health Care Campus
Introduction: Myopia has become an epidemic. We compiled data worldwide to reach a consensus for preferred clinical practice to decrease myopia progression.
Methods: A questionnaire was sent to all members of supra-national and some national pediatric ophthalmology and strabismus societies.
Results: The questionnaire was fully completed in 847 of 940 responses. The majority routinely treat to decrease myopia progression (524, 59.1%). The most common parameter to initiate treatment was a myopic increase of 1 diopter/year or more (246, 74.8%). Most respondents (242, 51.1%) did not know at what age response to treatment was most effective. Most (345, 70%) prescribed eye drops and the average age they were initiated was 5.2 (0.5 to 16 years old). Atropine 0.01% was the most popular (277, 63.4%) with the highest number of respondents that have not discontinued treatment in any of their patients (178, 79.5%) and showed the least number of respondents, who had reported a rebound effect (53, 45.7%). Most respondents opted for more time outdoors (394, 85.7%), to spend less time looking at screens (277, 60.2%), and decrease the use of smart phones (294, 63.9%).
Discussion: Most pediatric ophthalmologists use a variety of means to decrease myopia progression. Atropine 0.01% is the most popular and safe modality similarly to recent reports . However, there is no consensus when treatment should be initiated.
Conclusion: Further prospective studies are needed to elucidate the best timing to start treatment and the applicability of recent studies in the Asian population  to other ethnic groups.
References: 1. Huang J, Wen D, Wang Q, McAlinden C, Flitcroft I, Chen H, Saw SM, Chen H, Bao F, Zhao Y, Hu L, Li X, Gao R, Lu W, Du Y, Jinag Z, Yu A, Lian H, Jiang Q, Yu Y,
Qu J. Efficacy Comparison of 16 Interventions for Myopia Control in Children: A Network Meta-analysis. Ophthalmology. 2016 Apr;123(4):697-708. doi: 10.1016/j.ophtha.2015.11.010. Epub 2016 Jan 27.
2. Chia A, Lu QS, Tan D. Five-Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops. Ophthalmology. 2016 Feb;123(2):391-9. doi: 10.1016/j.ophtha.2015.07.004. Epub 2015 Aug 11.